Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 25;25(1):71.
doi: 10.1007/s10142-025-01579-0.

Cutting edge: ferroptosis in metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis and therapy

Affiliations
Review

Cutting edge: ferroptosis in metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis and therapy

Amr Ali Mohamed Abdelgawwad El-Sehrawy et al. Funct Integr Genomics. .

Abstract

Ferroptosis denotes a distinct form of controlled cell death marked by substantial iron buildup and significant lipid peroxidation, playing a crucial role in several disease processes linked to cell death. Given the liver's essential functions in iron and lipid metabolism and its vulnerability to oxidative damage, more research has investigated the correlation between ferroptosis and numerous hepatic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). NAFLD has arisen as a worldwide public health concern due to elevated morbidity and high death rates. The pathogenesis of MASLD remains incompletely elucidated. Recent data suggests that ferroptosis is crucial in the pathophysiology of MASLD; nevertheless, the specific processes by which ferroptosis influences MASLD remain unclear. The present review summarizes the molecular processes of ferroptosis and its intricate regulatory networks, outlines the differing impacts of ferroptosis at different stages of MASLD, and examines possible approaches targeting ferroptosis for the therapy of MASLD, suggesting a novel approach for its management.

Keywords: Ferroptosis; Iron; Lipid; MASLD; Pathogenesis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: None. Competing interests: The authors declare no competing interests.

References

    1. Aschemeyer S, Qiao B, Stefanova D, Valore EV, Sek AC, Ruwe TA, Vieth KR, Jung G, Casu C, Rivella S (2018) 'Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin'. Blood J Am Soc Hematol 131:899–910
    1. Baboota RK, Blüher M, Smith U (2021) Emerging role of bone morphogenetic protein 4 in metabolic disorders. Diabetes 70:303–312 - PubMed
    1. Bedogni G, Kahn HS, Bellentani S, Tiribelli C (2010) A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 10:98 - PubMed - PMC
    1. Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, Nomura DK, Dixon SJ, Olzmann JA (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575:688–692 - PubMed - PMC
    1. Billesbølle CB, Azumaya CM, Kretsch RC, Powers AS, Gonen S, Schneider S, Arvedson T, Dror RO, Cheng Y, Manglik A (2020) Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms. Nature 586:807–811 - PubMed - PMC

LinkOut - more resources